Alaunos Therapeutics Stock Performance
| TCRT Stock | USD 2.85 0.14 4.68% |
On a scale of 0 to 100, Alaunos Therapeutics holds a performance score of 8. The firm shows a Beta (market volatility) of -1.98, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Alaunos Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Alaunos Therapeutics is expected to outperform it. Please check Alaunos Therapeutics' total risk alpha, as well as the relationship between the downside variance and daily balance of power , to make a quick decision on whether Alaunos Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Alaunos Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Alaunos Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 5.65 | Five Day Return 24.58 | Year To Date Return 51.78 | Ten Year Return (99.85) | All Time Return (99.88) |
Last Split Factor 1:10 | Last Split Date 2024-07-18 |
1 | Is Alaunos Therapeutics Inc. stock entering bullish territory - Weekly Risk Report Reliable Intraday Trade Alerts - Newser | 09/02/2025 |
2 | 12 Health Care Stocks Moving In Fridays Pre-Market Session | 10/10/2025 |
3 | News impact scoring models applied to Alaunos Therapeutics Inc. - Earnings Risk Summary Daily Technical Forecast Reports - newser.com | 10/15/2025 |
4 | Is Alaunos Therapeutics Inc. stock a safe haven asset - Global Markets Stepwise Trade Execution Plans - newser.com | 10/20/2025 |
5 | Acquisition by Jerman Michael Allen of 10000 shares of Alaunos Therapeutics at 3.4 subject to Rule 16b-3 | 10/27/2025 |
6 | How hedge fund analytics apply to Alaunos Therapeutics Inc. stock - Weekly Profit Report Community Verified Trade Signals - newser.com | 10/28/2025 |
7 | Market reaction to Alaunos Therapeutics Inc.s recent news - Quarterly Portfolio Review Consistent Growth Equity Picks - newser.com | 11/03/2025 |
8 | Order flow analysis tools used on Alaunos Therapeutics Inc. - 2025 Key Lessons Daily Volume Surge Trade Alerts - newser.com | 11/06/2025 |
9 | Is Alaunos Therapeutics Inc. stock cheap compared to fundamentals - Quarterly Trade Summary Weekly Watchlist for Consistent Profits - newser.com | 11/12/2025 |
| Begin Period Cash Flow | 6.1 M |
Alaunos Therapeutics Relative Risk vs. Return Landscape
If you would invest 225.00 in Alaunos Therapeutics on August 15, 2025 and sell it today you would earn a total of 77.00 from holding Alaunos Therapeutics or generate 34.22% return on investment over 90 days. Alaunos Therapeutics is currently generating 0.6902% in daily expected returns and assumes 6.8282% risk (volatility on return distribution) over the 90 days horizon. In different words, 61% of stocks are less volatile than Alaunos, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Alaunos Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alaunos Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Alaunos Therapeutics, and traders can use it to determine the average amount a Alaunos Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1011
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TCRT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.83 actual daily | 61 61% of assets are less volatile |
Expected Return
| 0.69 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 8 92% of assets perform better |
Based on monthly moving average Alaunos Therapeutics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Alaunos Therapeutics by adding it to a well-diversified portfolio.
Alaunos Therapeutics Fundamentals Growth
Alaunos Stock prices reflect investors' perceptions of the future prospects and financial health of Alaunos Therapeutics, and Alaunos Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Alaunos Stock performance.
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.54 | ||||
| Operating Margin | (672.83) % | ||||
| Current Valuation | 577.21 K | ||||
| Shares Outstanding | 2.21 M | ||||
| Price To Book | 1.81 X | ||||
| Price To Sales | 1,157 X | ||||
| Revenue | 10 K | ||||
| Gross Profit | (581 K) | ||||
| EBITDA | (4.68 M) | ||||
| Net Income | (4.68 M) | ||||
| Cash And Equivalents | 60.01 M | ||||
| Cash Per Share | 0.28 X | ||||
| Total Debt | 692 K | ||||
| Debt To Equity | 0.69 % | ||||
| Current Ratio | 2.29 X | ||||
| Book Value Per Share | 1.76 X | ||||
| Cash Flow From Operations | (4.97 M) | ||||
| Earnings Per Share | (2.47) X | ||||
| Market Capitalization | 6.94 M | ||||
| Total Asset | 2.75 M | ||||
| Retained Earnings | (920.45 M) | ||||
| Working Capital | 2.06 M | ||||
About Alaunos Therapeutics Performance
Assessing Alaunos Therapeutics' fundamental ratios provides investors with valuable insights into Alaunos Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Alaunos Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.7 K | 1.5 K | |
| Return On Tangible Assets | (1.70) | (1.78) | |
| Return On Capital Employed | (2.33) | (2.45) | |
| Return On Assets | (1.70) | (1.78) | |
| Return On Equity | (2.27) | (2.15) |
Things to note about Alaunos Therapeutics performance evaluation
Checking the ongoing alerts about Alaunos Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Alaunos Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Alaunos Therapeutics is way too risky over 90 days horizon | |
| Alaunos Therapeutics appears to be risky and price may revert if volatility continues | |
| Alaunos Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 10 K. Net Loss for the year was (4.68 M) with loss before overhead, payroll, taxes, and interest of (581 K). | |
| Alaunos Therapeutics currently holds about 60.01 M in cash with (4.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28. | |
| Alaunos Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Is Alaunos Therapeutics Inc. stock cheap compared to fundamentals - Quarterly Trade Summary Weekly Watchlist for Consistent Profits - newser.com |
- Analyzing Alaunos Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Alaunos Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Alaunos Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Alaunos Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Alaunos Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Alaunos Therapeutics' stock. These opinions can provide insight into Alaunos Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Alaunos Stock Analysis
When running Alaunos Therapeutics' price analysis, check to measure Alaunos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alaunos Therapeutics is operating at the current time. Most of Alaunos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alaunos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alaunos Therapeutics' price. Additionally, you may evaluate how the addition of Alaunos Therapeutics to your portfolios can decrease your overall portfolio volatility.